Base de dados : MEDLINE
Pesquisa : D02.806.400.249.350 [Categoria DeCS]
Referências encontradas : 11230 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1123 ir para página                         

  1 / 11230 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28470465
[Au] Autor:Myers AL; Zhang YP; Kawedia JD; Zhou X; Sobocinski SM; Metcalfe MJ; Kramer MA; Dinney CPN; Kamat AM
[Ad] Endereço:Department of Pharmacy Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. almyers@mdanderson.org.
[Ti] Título:Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration.
[So] Source:Drugs R D;17(2):297-304, 2017 Jun.
[Is] ISSN:1179-6901
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Mitomycin C (MMC) is an antitumor agent that is often administered intravesically to treat bladder cancer. Pharmacologically optimized studies have suggested varying methods to optimize delivery, with drug concentration and solution volume being the main drivers. However, these MMC concentrations (e.g. 2.0 mg/mL) supersede its solubility threshold, raising major concerns of inferior drug delivery. OBJECTIVE: In this study, we seek to confirm that the pharmacologically optimized MMC concentrations are achievable in clinical practice through careful modifications of the solution preparation methods. METHODS: MMC admixtures (1.0 and 2.0 mg/mL) were prepared in normal saline using conventional and alternative compounding methods. Conventional methodology resulted in poorly soluble solutions, with many visible particulates and crystallates. However, special compounding methods, which included incubation of solutions at 50 °C for 50 min followed by storage at 37 °C, were sufficient to solubilize drug. Chemical degradation of MMC solutions was determined over 6 h using high-performance liquid chromatography (HPLC) analytics, while physical stability was tested in parallel. RESULTS: Immediately following the 50 min incubation, both MMC solutions exhibited approximately 5-7% drug degradation. Based on the measured concentrations and linear regression of degradation plots, additional storage of these solutions at 37 °C for 5 h retained chemical stability criterion (< 10% overall drug loss). No physical changes were observed in any solutions at any test time points. CONCLUSION: We recommend that the described alternative preparation methods may improve intravesicular delivery of MMC in this urological setting, and advise that clinicians employing these changes should closely monitor patients for MMC toxicities and pharmacodynamics (change in clinical outcomes) that result from the potential enhancement of MMC exposure in the bladder.
[Mh] Termos MeSH primário: Antineoplásicos/química
Mitomicina/química
Soluções Farmacêuticas/química
[Mh] Termos MeSH secundário: Administração Intravesical
Estabilidade de Medicamentos
Solubilidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Pharmaceutical Solutions); 50SG953SK6 (Mitomycin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1007/s40268-017-0183-y


  2 / 11230 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463160
[Au] Autor:Olsen JR; Moughan J; Myerson R; Abitbol A; Doncals DE; Johnson D; Schefter TE; Chen Y; Fisher B; Michalski J; Narayan S; Chang A; Crane CH; Kachnic L
[Ad] Endereço:University of Colorado Denver, Aurora, Colorado. Electronic address: Jeffrey.R.Olsen@ucdenver.edu.
[Ti] Título:Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):400-408, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: NRG Oncology RTOG 0529 assessed the feasibility of dose-painted intensity modulated radiation therapy (DP-IMRT) to reduce the acute morbidity of chemoradiation with 5-fluorouracil (5FU) and mitomycin-C (MMC) for T2-4N0-3M0 anal cancer. This secondary analysis was performed to identify patient and treatment factors associated with acute and late gastrointestinal (GI) adverse events (AEs). METHODS AND MATERIALS: NRG Oncology RTOG 0529 treatment plans were reviewed to extract dose-volume data for tightly contoured small bowel, loosely contoured anterior pelvic contents (APC), and uninvolved colon outside the target volume (UC). Univariate logistic regression was performed to evaluate association between volumes of each structure receiving doses ≥5 to 60 Gy (V5-V60) in 5-Gy increments between patients with and without grade ≥2 acute and late GI AEs, and grade ≥3 acute GI AEs. Additional patient and treatment factors were evaluated in multivariate logistic regression (acute AEs) or Cox proportional hazards models (late AEs). RESULTS: Among 52 evaluable patients, grade ≥2 acute, grade ≥2 late, and grade ≥3 acute GI AEs were observed in 35, 17, and 10 patients, respectively. Trends (P<.05) toward statistically significant associations were observed between grade ≥2 acute GI AEs and small bowel dose (V20-V40), grade ≥2 late GI AEs and APC dose (V60), grade ≥3 acute GI AEs and APC dose (V5-V25), increasing age, tumor size >4 cm, and worse Zubrod performance status. Small bowel volumes of 186.0 cc, 155.0 cc, 41.0 cc, and 30.4 cc receiving doses greater than 25, 30, 35, and 40 Gy, respectively, correlated with increased risk of acute grade ≥2 GI AEs. CONCLUSIONS: Acute and late GI AEs from 5FU/MMC chemoradiation using DP-IMRT correlate with radiation dose to the small bowel and APC. Such associations will be incorporated in the dose-volume normal tissue constraint design for future NRG oncology anal cancer studies.
[Mh] Termos MeSH primário: Antineoplásicos/efeitos adversos
Neoplasias do Ânus/terapia
Carcinoma de Células Escamosas/terapia
Quimiorradioterapia/efeitos adversos
Intestino Delgado/efeitos da radiação
Radioterapia de Intensidade Modulada/efeitos adversos
[Mh] Termos MeSH secundário: Doença Aguda
Adulto
Fatores Etários
Idoso
Idoso de 80 Anos ou mais
Antineoplásicos/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Neoplasias do Ânus/diagnóstico por imagem
Neoplasias do Ânus/patologia
Carcinoma de Células Escamosas/patologia
Quimiorradioterapia/métodos
Colo/diagnóstico por imagem
Estudos de Viabilidade
Feminino
Fluoruracila/administração & dosagem
Fluoruracila/efeitos adversos
Seres Humanos
Intestino Delgado/diagnóstico por imagem
Masculino
Meia-Idade
Mitomicina/administração & dosagem
Mitomicina/efeitos adversos
Órgãos em Risco/diagnóstico por imagem
Órgãos em Risco/patologia
Órgãos em Risco/efeitos da radiação
Pelve/diagnóstico por imagem
Modelos de Riscos Proporcionais
Curva ROC
Dosagem Radioterapêutica
Radioterapia de Intensidade Modulada/métodos
Análise de Regressão
Carga Tumoral
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Antineoplastic Agents); 50SG953SK6 (Mitomycin); U3P01618RT (Fluorouracil)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  3 / 11230 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29422751
[Au] Autor:Marco S; Damji KF; Nazarali S; Rudnisky CJ
[Ad] Endereço:Department of Ophthalmology, University of Nairobi, Nairobi, Kenya.
[Ti] Título:Cataract and Glaucoma Surgery: Endoscopic Cyclophotocoagulation versus Trabeculectomy.
[So] Source:Middle East Afr J Ophthalmol;24(4):177-182, 2017 Oct-Dec.
[Is] ISSN:0975-1599
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To compare the efficacy and safety of endoscopic cyclophotocoagulation (ECP) versus trabeculectomy with mitomycin C (trab) in combination with cataract surgery. MATERIALS AND METHODS: We evaluated the 6-month results of patients undergoing phacoemulsification (phaco) with either ECP or trab. The primary outcome was mean intraocular pressure (IOP) at 6 months; secondary outcomes were change in glaucoma medications, visual acuity, intraocular inflammation, and postoperative complications. Complete success was a target IOP of <21 mmHg and >6 mmHg without glaucoma medications. Qualified success was target IOP achieved through glaucoma medications. RESULTS: We evaluated 53 eyes of 53 patients; 24 (45.3%) eyes were treated with ECP-phaco and 29 (54.7%) with trab-phaco. At 6 months, there was no significant difference in mean IOP of the two groups (ECP-phaco 14.2 ± 3.6 mmHg; trab-phaco 13.0 ± 2.5 mmHg; = 0.240). Six (25.0%) ECP-phaco eyes and 20 (69.0%) trab-phaco eyes achieved complete success ( = 0.002). Qualified success was achieved in 18 (75.0%) ECP-phaco eyes and 9 (31.0%) trab-phaco eyes ( = 0.002). The mean reduction of medication from baseline was significant (ECP-phaco 1.2 ± 1.1; trab-phaco 2.1 ± 1.5; = 0.020). ECP-phaco resulted in more IOP spikes on the 1 postoperative day ( = 0.040) and more anterior cellular reaction at 1 week and 1 month compared to trab-phaco ( < 0.05). The rate of postoperative complications was not significantly different between groups. CONCLUSION: At 6 months, ECP-phaco demonstrated similar improvements in IOP and visual acuity compared to trab-phaco. However, ECP-phaco patients had higher incidences of immediate postoperative IOP spikes and anterior chamber inflammation as well as requiring additional medications postoperatively.
[Mh] Termos MeSH primário: Corpo Ciliar/cirurgia
Glaucoma/cirurgia
Fotocoagulação a Laser/métodos
Facoemulsificação
Trabeculectomia/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Alquilantes/administração & dosagem
Endoscopia
Feminino
Glaucoma/fisiopatologia
Seres Humanos
Pressão Intraocular/fisiologia
Masculino
Meia-Idade
Mitomicina/administração & dosagem
Tonometria Ocular
Acuidade Visual/fisiologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alkylating Agents); 50SG953SK6 (Mitomycin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180210
[St] Status:MEDLINE
[do] DOI:10.4103/meajo.MEAJO_232_16


  4 / 11230 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29227512
[Au] Autor:Anumanthan G; Sharma A; Waggoner M; Hamm CW; Gupta S; Hesemann NP; Mohan RR
[Ti] Título:Efficacy and Safety Comparison Between Suberoylanilide Hydroxamic Acid and Mitomycin C in Reducing the Risk of Corneal Haze After PRK Treatment In Vivo.
[So] Source:J Refract Surg;33(12):834-839, 2017 Dec 01.
[Is] ISSN:1081-597X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: This study compared the efficacy and safety of suberoylanilide hydroxamic acid (SAHA) and mitomycin C (MMC) up to 4 months in the prevention of corneal haze induced by photorefractive keratectomy (PRK) in rabbits in vivo. METHODS: Corneal haze in rabbits was produced with -9.00 diopter PRK. A single application of SAHA (25 µM) or MMC (0.02%) was applied topically immediately after PRK. Effects of the two drugs were analyzed by slit-lamp microscope, specular microscope, TUNEL assay, and immunofluorescence. RESULTS: Single topical adjunct use of SAHA (25 µM) or MMC (0.02%) after PRK attenuated more than 95% corneal haze and myofibroblast formation (P < .001). SAHA did not reduce keratocyte density, cause keratocyte apoptosis, or increase immune cell infiltration compared to MMC (P < .01 or .001). Furthermore, SAHA dosing did not compromise corneal endothelial phenotype, density, or function in rabbit eyes, whereas MMC application did (P < .01 or .001). CONCLUSIONS: SAHA and MMC significantly decreased corneal haze after PRK in rabbits in vivo. SAHA exhibited significantly reduced short- and long-term damage to the corneal endothelium compared to MMC in rabbits. SAHA is an effective and potentially safer alternative to MMC for the prevention of corneal haze after PRK. Clinical trials are warranted. [J Refract Surg. 2017;33(12):834-839.].
[Mh] Termos MeSH primário: Alquilantes/uso terapêutico
Opacidade da Córnea/prevenção & controle
Modelos Animais de Doenças
Inibidores de Histona Desacetilases/uso terapêutico
Ácidos Hidroxâmicos/uso terapêutico
Mitomicina/uso terapêutico
Ceratectomia Fotorrefrativa/efeitos adversos
[Mh] Termos MeSH secundário: Alquilantes/efeitos adversos
Animais
Apoptose
Córnea/cirurgia
Opacidade da Córnea/etiologia
Técnica Indireta de Fluorescência para Anticorpo
Inibidores de Histona Desacetilases/efeitos adversos
Ácidos Hidroxâmicos/efeitos adversos
Marcação In Situ das Extremidades Cortadas
Mitomicina/efeitos adversos
Coelhos
Lâmpada de Fenda
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alkylating Agents); 0 (Histone Deacetylase Inhibitors); 0 (Hydroxamic Acids); 50SG953SK6 (Mitomycin); 58IFB293JI (vorinostat)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE
[do] DOI:10.3928/1081597X-20170921-02


  5 / 11230 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29227509
[Au] Autor:Garcia-Gonzalez M; Drake Rodriguez-Casanova P; Rodriguez-Perez I; Rodero A; Teus MA
[Ti] Título:Long-term Follow-up of LASEK With Mitomycin C Performed to Correct Myopia in Thin Corneas.
[So] Source:J Refract Surg;33(12):813-819, 2017 Dec 01.
[Is] ISSN:1081-597X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To evaluate the long-term outcomes of laser-assisted subepithelial keratomileusis (LASEK) with intraoperative use of mitomycin C (MMC) performed on thin corneas for the correction of myopia. METHODS: This retrospective cohort study included 100 eyes with a preoperative central corneal thickness (CCT) thinner than 500 µm that underwent LASEK + MMC with at least 6 years of follow-up. Stability of visual acuity and refraction and the efficacy, safety, and predictability at the examinations 3 months and the last annual postoperative visit were analyzed. RESULTS: Preoperative CCT was 482.9 ± 14.7 µm (range: 433 to 499 µm). Mean preoperative spherical equivalent was -4.09 ± 2.3 diopters (D). At the 3-month postoperative visit, mean CCT was 419.79 ± 32.6 µm. The residual spherical equivalent showed a statistically significant regression (P = .001) in the comparison between the 3-month and the last annual postoperative visit. The efficacy index showed a significant decrease (P = .01) and the safety index remained stable around 0.96. Six or more years after the surgery, 85 eyes (85%) were within ±0.50 D and 94 eyes (94%) eyes were within ±1.00 D of emmetropia. The topography did not show signs of secondary corneal ectasia in any eye. CONCLUSIONS: LASEK with intraoperative use of MMC seems to be safe, effective, and predictable to correct myopia in corneas thinner than 500 µm and with normal preoperative topography, providing good visual and refractive outcomes with no topographic signs of corneal ectasia in a mean 6.5-year follow-up. [J Refract Surg. 2017;33(12):813-819.].
[Mh] Termos MeSH primário: Alquilantes/administração & dosagem
Córnea/patologia
Ceratectomia Subepitelial Assistida por Laser/métodos
Lasers de Excimer/uso terapêutico
Mitomicina/administração & dosagem
Miopia/terapia
[Mh] Termos MeSH secundário: Adulto
Terapia Combinada
Paquimetria Corneana
Topografia da Córnea
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Miopia/tratamento farmacológico
Miopia/fisiopatologia
Miopia/cirurgia
Refração Ocular
Estudos Retrospectivos
Acuidade Visual
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alkylating Agents); 50SG953SK6 (Mitomycin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171212
[St] Status:MEDLINE
[do] DOI:10.3928/1081597X-20171004-06


  6 / 11230 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29372785
[Au] Autor:Tarasov VA; Boyko NV; Makhotkin MA; Shin EF; Tyutyakina MG; Chikunov IE; Naboka AV; Mashkarina AN; Kirpiy AA; Matishov DG
[Ti] Título:[The miRNA aberrant expression dependence on DNA methylation in HeLa cells treated with mitomycin C].
[So] Source:Genetika;52(11):1233-40, 2016 Nov.
[Is] ISSN:0016-6758
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The dependence of expression of miRNAs and their precursors (pre-miRNAs) on the DNA methylation level in HeLa cells 8 days after mitomycin C treatment was studied. A massive parallel DNA sequencing method was applied to analyze miRNA expression. 5-Azacytidine (DNA methylation inhibitor) was added to the medium 6 days after mutagenic agent exposure. The results indicated that the change in expression for some mature miRNAs (39 of 61) was accompanied by the change in the expression of their pre-miRNAs, while there were no significant changes in the expression of pre-miRNA for other mature miRNAs (22 of 61). The aberrant expression was maintained by 8 of 61 mature miRNAs and 6 of 55 pre-miRNAs in the induced HeLa cells after 5-azacytidine treatment. In addition, the expression of more than 90% of miRNAs, which indicated a significant change in expression after mitomycin C treatment, does not depend or depends slightly on the DNA methylation level in HeLa cells without mitomycin C treatment. The results suggest that mitomycin C induces aberrant DNA methylation which affects maintenance of changes in the miRNA expression in cell generations after mutagen treatment.
[Mh] Termos MeSH primário: Metilação de DNA
Regulação da Expressão Gênica/efeitos dos fármacos
MicroRNAs
Mitomicina/farmacologia
[Mh] Termos MeSH secundário: Metilação de DNA/efeitos dos fármacos
Metilação de DNA/genética
Células HeLa
Seres Humanos
MicroRNAs/biossíntese
MicroRNAs/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (MicroRNAs); 50SG953SK6 (Mitomycin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180127
[St] Status:MEDLINE


  7 / 11230 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29217030
[Au] Autor:Abd El Ghafar AS; El-Kannishy AM; Elwan MM; Sabry D; Kishk HM; Elhefney EM
[Ad] Endereço:Ophthalmology Department, Ophthalmic Center, Mansoura University, Mansoura, Egypt.. Electronic address: aiman_eg_123@yahoo.com.
[Ti] Título:Perforated punctal plugs with adjuvant use of mitomycin-C in management of acquired external punctal stenosis grades 0 and 1.
[So] Source:Can J Ophthalmol;52(6):606-610, 2017 Dec.
[Is] ISSN:1715-3360
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the use of perforated punctal plugs with adjuvant application of mitomycin-C in the management of acquired external punctal stenosis grades 0 and 1. METHODS: This is a prospective interventional case series including 30 eyes of 30 patients with acquired external punctal stenosis of the lower punctum of grades 0 and 1 presenting with epiphora. They were examined to exclude other causes of lacrimation and epiphora: Slit-lamp assessment of the stenosed punctum and grading was done, probing was done to exclude associated canalicular stenosis, and syringing was done to exclude nasolacrimal duct obstruction. For all cases, dilatation was done, followed by application of mitomycin-C, and perforated punctal plugs were then inserted. Plugs were removed after 6 months, and anatomical and functional success were assessed and followed during and for 6 months after removal of the plugs. RESULTS: The study included 30 patients with acquired external punctal stenosis: 9 males (30%) and 21 females (70%) with a mean age of 62.83 ± 8.3 years. Punctal stenosis grade 0 (no punctum) occurred in 9 cases (30%), and grade 1 (the punctum is covered by a membrane) occurred in 21 cases (70%). Six months after removal of the plugs, epiphora improved in 93.3% of patients, and fluorescein dye disappearance test results improved in 90% of patients; 6.7% of cases had early extrusion of the plug, and 3.3% had granuloma formation. CONCLUSIONS: Application of perforated punctal plugs combined with mitomycin-C is a simple and efficient technique in the management of tight acquired external punctal stenosis.
[Mh] Termos MeSH primário: Alquilantes/administração & dosagem
Pálpebras/patologia
Aparelho Lacrimal/patologia
Obstrução dos Ductos Lacrimais/terapia
Mitomicina/administração & dosagem
Plug Lacrimal
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Terapia Combinada
Desenho de Equipamento
Pálpebras/efeitos dos fármacos
Feminino
Corantes Fluorescentes/administração & dosagem
Seres Humanos
Obstrução dos Ductos Lacrimais/classificação
Obstrução dos Ductos Lacrimais/patologia
Masculino
Meia-Idade
Estudos Prospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alkylating Agents); 0 (Fluorescent Dyes); 50SG953SK6 (Mitomycin)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171226
[Lr] Data última revisão:
171226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE


  8 / 11230 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28468910
[Au] Autor:Dapa T; Fleurier S; Bredeche MF; Matic I
[Ad] Endereço:INSERM U1001, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine Paris Descartes, 75014, France.
[Ti] Título:The SOS and RpoS Regulons Contribute to Bacterial Cell Robustness to Genotoxic Stress by Synergistically Regulating DNA Polymerase Pol II.
[So] Source:Genetics;206(3):1349-1360, 2017 07.
[Is] ISSN:1943-2631
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Mitomycin C (MMC) is a genotoxic agent that induces DNA cross-links, DNA alkylation, and the production of reactive oxygen species (ROS). MMC induces the SOS response and RpoS regulons in SOS-encoded functions are required for DNA repair, whereas the RpoS regulon is typically induced by metabolic stresses that slow growth. Thus, induction of the RpoS regulon by MMC may be coincidental, because DNA damage slows growth; alternatively, the RpoS regulon may be an adaptive response contributing to cell survival. In this study, we show that the RpoS regulon is primarily induced by MMC-induced ROS production. We also show that RpoS regulon induction is required for the survival of MMC-treated growing cells. The major contributor to RpoS-dependent resistance to MMC treatment is DNA polymerase Pol II, which is encoded by the gene belonging to the SOS regulon. The observation that gene expression is controlled by the two major stress response regulons that are required to maximize survival and fitness further emphasizes the key role of this DNA polymerase as an important factor in genome stability.
[Mh] Termos MeSH primário: Proteínas de Bactérias/metabolismo
Dano ao DNA
Proteínas de Escherichia coli/metabolismo
Resposta SOS (Genética)
Fator sigma/metabolismo
[Mh] Termos MeSH secundário: Antibacterianos/toxicidade
Proteínas de Bactérias/genética
Escherichia coli/efeitos dos fármacos
Escherichia coli/genética
Escherichia coli/metabolismo
Proteínas de Escherichia coli/genética
Mitomicina/toxicidade
Mutagênicos/toxicidade
Espécies Reativas de Oxigênio/metabolismo
Regulon
Fator sigma/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Bacterial Proteins); 0 (Escherichia coli Proteins); 0 (Mutagens); 0 (Reactive Oxygen Species); 0 (Sigma Factor); 0 (polB protein, E coli); 0 (sigma factor KatF protein, Bacteria); 50SG953SK6 (Mitomycin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171213
[Lr] Data última revisão:
171213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1534/genetics.116.199471


  9 / 11230 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28977004
[Au] Autor:Wasielica-Poslednik J; Schmeisser J; Hoffmann EM; Weyer-Elberich V; Bell K; Lorenz K; Pfeiffer N
[Ad] Endereço:Department of Ophthalmology, University Medical Center, Johannes Gutenberg- University, Mainz, Germany.
[Ti] Título:Fluctuation of intraocular pressure in glaucoma patients before and after trabeculectomy with mitomycin C.
[So] Source:PLoS One;12(10):e0185246, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Intraocular pressure (IOP) fluctuation is considered as a risk factor for glaucoma progression. We investigated IOP values and IOP fluctuation before and after trabeculectomy (TE) with mitomycin C (MMC) measured by 48-hour diurnal-nocturnal-IOP-profiles (DNP). METHODS: Pre- and postoperative DNPs of 92 eyes undergoing primary TE with MMC were analysed. Each 48-hour IOP-profile involved 10 IOP measurements (8:00 a.m., 2:00 p.m., 6:00 p.m., and 9:00 p.m. in sitting and at 00:00 in supine position). The "preoperative DNP" was performed a few weeks before TE. The "postoperative DNP" was performed at least six months (range: 6 months-2 years) after TE. Mean IOP values and IOP fluctuations were calculated. RESULTS: After TE with MMC mean IOP was reduced from 16.94±3.83 to 11.26±3.77 mmHg at daytime and from 18.17±4.26 to 11.76±3.90 mmHg at night. At daytime mean IOP-fluctuation decreased from 8.61±4.19 to 4.92±2.52 mmHg, at night from 3.15±2.95 to 1.99±1.82 mmHg. Mean IOP was lower on the second day of the preoperative DNP. This effect was not present in the postoperative DNP. Preoperatively, IOP was controlled in all eyes with a mean of 3.22±0.94 antiglaucomatous agents. Postoperatively, IOP≤15 mmHg was achieved in 71.7%, IOP≤18 mmHg in 77.1% and a decrease in IOP of >30% in 47.8% without antiglaucomatous therapy. Postoperatively, pseudophakia was associated by a higher mean IOP-fluctuation compared to the phakic eyes. CONCLUSIONS: TE with MMC significantly reduces both mean IOP-values and IOP- fluctuations at day and night at least 6 months postoperatively. The effect of TE on the IOP fluctuation was less pronounced in pseudophakic eyes.
[Mh] Termos MeSH primário: Glaucoma/fisiopatologia
Pressão Intraocular
Mitomicina/administração & dosagem
Trabeculectomia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Glaucoma/cirurgia
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
50SG953SK6 (Mitomycin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171005
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0185246


  10 / 11230 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28850613
[Au] Autor:Naito T; Fujiwara M; Miki T; Araki R; Fujiwara A; Shiode Y; Morizane Y; Nagayama M; Shiraga F
[Ad] Endereço:Department of Ophthalmology, Okayama University Medical School Hospital, Okayama, Japan.
[Ti] Título:Effect of trabeculectomy on visual field progression in Japanese progressive normal-tension glaucoma with intraocular pressure < 15 mmHg.
[So] Source:PLoS One;12(8):e0184096, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We examined the effectiveness of trabeculectomy in decreasing the slope of mean deviation (MD) in Japanese patients with progressive normal-tension glaucoma (NTG) at low intraocular pressure (IOP) levels. The charts of patients who had undergone initial trabeculectomy with adjunctive mitomycin C for progressive NTG with medically controlled IOP < 15 mmHg in 2010-2013 were retrospectively reviewed. Seventeen eyes of 13 NTG patients who had undergone at least 5 times of visual field (VF) examinations in both of preoperatively and postoperatively with postoperative follow-up of ≥ 2 years were enrolled. Preoperative and postoperative MD slopes were compared to evaluate the effectiveness of trabeculectomy in slowing progression of VF. Mean IOP (8.1 ± 2.9 mmHg) and number of IOP-lowering medications (0.8 ± 1.5) were significantly lower postoperatively than preoperatively (13.9 ± 0.9 mmHg; P < 0.001 and 3.0± 0.4; P < 0.0001). In total, 91.7% of eyes with single-digit IOP postoperatively showed improvement in MD slope, whereas only 20.0% of eyes with IOP ≥ 10 mmHg postoperatively showed the improvement. Three eyes (17.6%) showed a decrease in visual acuity (VA) of ≥ 0.1 unit; this group had a lower mean postoperative IOP (6.0 ± 1.0 vs. 8.6 ± 3.0 mmHg; P = 0.1717) and a higher mean IOP reduction rate (56.2 vs. 38.5%; P = 0.8296) than eyes with a VA decrease of < 0.1 unit or no change. Thus, in this analysis of Japanese NTG patients with medically controlled IOP < 15 mmHg, achieving an IOP < 10 mmHg with trabeculectomy was beneficial for reducing the VF progression rate in progressive NTG at low IOP levels. However, an IOP < 7 mmHg by surgery would be required careful attention to VA decline.
[Mh] Termos MeSH primário: Pressão Intraocular/fisiologia
Glaucoma de Baixa Tensão/cirurgia
Trabeculectomia
Campos Visuais/fisiologia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Progressão da Doença
Feminino
Seres Humanos
Japão
Glaucoma de Baixa Tensão/fisiopatologia
Masculino
Meia-Idade
Mitomicina/uso terapêutico
Estudos Retrospectivos
Tonometria Ocular
Resultado do Tratamento
Acuidade Visual/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
50SG953SK6 (Mitomycin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170830
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0184096



página 1 de 1123 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde